The Amyloidosis Forum | November 18, 2022 | Afternoon Sessions

Recording of the Afternoon Sessions from the Amyloidosis Forum: Potential Pathways for Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis, hosted at the U.S. Food and Drug Administration's White Oak Campus in Silver Spring, Maryland on November 18, 2022.

The Afternoon Sessions were moderated by Preston Dunnmon MD, MBA, FACP, FACC, Vice President of Data Science, Cardiovascular, Metabolism, & Pulmonary Hypertension at Janssen Research and Development.

Each session can be viewed at the following timestamps:

0:00 - Laying the Groundwork for Qualifying Images as Potential Clinical Outcome Surrogates: How to Get There from Here (Preston Dunnmon)
1:03 - Patient Perspectives: The Value of Imaging (Isabelle Lousada)
5:57 - Case Study from Another Rare Disease: Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) (Ahmad Masri)
18:14 - Images as Predictive Biomarkers (Trial Endpoint Surrogates): Current Thinking by the Health Authorities (Norman Stockbridge (FDA), Rosalyn Adigun (FDA), Joseph Rajendran (FDA), August Hofling (FDA), Nicole Gormley (FDA), Cynthia Welsh (FDA), Krishna Prasad (MHRA), Clemens Mittmann (EMA), & Jean-Michel Race (EMA))
1:08:26 - NIH HeartShare Study and BioData Catalyst (Vandana Sachdev)
1:27:47 - Moderated Discussion: Potential Pathway(s) for Imaging Biomarker Development in AL and ATTR Amyloidosis
2:13:38 - Closing Remarks (Isabelle Lousada & Rosalyn Adigun)

Meeting recorded live via Zoom
Be the first to comment